Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 4
1991 2
1992 4
1993 6
1994 3
1995 3
1996 6
1997 9
1998 9
1999 9
2000 14
2001 4
2002 4
2003 9
2004 8
2005 7
2006 8
2007 6
2008 5
2009 7
2010 3
2011 6
2012 16
2013 18
2014 16
2015 12
2016 16
2017 26
2018 30
2019 32
2020 32
2021 17
2022 28
2023 34
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Results by year

Filters applied: . Clear all
Page 1
14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A, Hacoon J, Heluwaert F, Mion F, Lamarque D, Moussata D, Mimouni M, Delchier JC, Durand-Zaleski I, Audureau E, Bastuji-Garin S; HEPYSE Study Group. Amiot A, et al. Among authors: durand zaleski i. Helicobacter. 2024 Mar-Apr;29(2):e13076. doi: 10.1111/hel.13076. Helicobacter. 2024. PMID: 38680067 Clinical Trial.
Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.
Dupas B, Castro-Farias D, Girmens JF, Eginay A, Couturier A, Villeroy F, Delyfer MN, Creuzot-Garcher C, Giocanti-Auregan A, Béral L, Arndt C, Mesnard C, Vicaut E, Chaumet-Riffaud P, Durand-Zaleski I, Paques M. Dupas B, et al. Among authors: durand zaleski i. Trials. 2024 Apr 22;25(1):273. doi: 10.1186/s13063-024-07994-1. Trials. 2024. PMID: 38649937 Free PMC article.
Weight telemonitoring of heart failure versus standard of care in a real-world setting: Results on mortality and hospitalizations in a 6-month nationwide matched cohort study.
Roubille F, Mercier G, Lancman G, Pasche H, Alami S, Delval C, Bessou A, Vadel J, Rey A, Duret S, Abraham E, Chatellier G, Durand Zaleski I. Roubille F, et al. Among authors: durand zaleski i. Eur J Heart Fail. 2024 Mar 7. doi: 10.1002/ejhf.3191. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38450858
Cost-effectiveness of stepwise provisional versus systematic dual stenting strategies in patients with distal bifurcation left main stem lesions: economic analysis of the EBC MAIN trial.
Le Bras A, Hildick-Smith D, Nze Ossima A, Supplisson O, Egred M, Brunel P, Banning AP, Morice MC, Durand-Zaleski I. Le Bras A, et al. Among authors: durand zaleski i. Open Heart. 2024 Jan 19;11(1):e002479. doi: 10.1136/openhrt-2023-002479. Open Heart. 2024. PMID: 38242557 Free PMC article.
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, Connolly S, Lonn E, Dagenais GR, Branch KRH, Wang WJ, Bhatt DL, Probstfield J, Ertl G, Störk S, Steg PG, Aboyans V, Durand-Zaleski I, Ryden L, Yusuf S; COMPASS Investigators. Lamy A, et al. Among authors: durand zaleski i. Am J Cardiovasc Drugs. 2024 Jan;24(1):117-127. doi: 10.1007/s40256-023-00620-6. Epub 2023 Dec 28. Am J Cardiovasc Drugs. 2024. PMID: 38153624 Free PMC article. Clinical Trial.
387 results